These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36965207)

  • 1. To fly or not to fly: Stereotactic MR-guided adaptive radiotherapy effectively treats ultracentral lung tumors with favorable long-term outcomes.
    Regnery S; Katsigiannopulos E; Hoegen P; Weykamp F; Sandrini E; Held T; Deng M; Eichkorn T; Buchele C; Rippke C; Renkamp CK; König L; Lang K; Thomas M; Winter H; Adeberg S; Klüter S; Debus J; Hörner-Rieber J
    Lung Cancer; 2023 May; 179():107175. PubMed ID: 36965207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Magnetic resonance guided adaptive stereotactic body radiotherapy for lung tumors in ultracentral location: the MAGELLAN trial (ARO 2021-3).
    Regnery S; Ristau J; Weykamp F; Hoegen P; Sprengel SD; Paul KM; Buchele C; Klüter S; Rippke C; Renkamp CK; Pohl M; Meis J; Welzel T; Adeberg S; Koerber SA; Debus J; Hörner-Rieber J
    Radiat Oncol; 2022 May; 17(1):102. PubMed ID: 35614486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive MR-Guided Stereotactic Radiotherapy is Beneficial for Ablative Treatment of Lung Tumors in High-Risk Locations.
    Regnery S; Buchele C; Weykamp F; Pohl M; Hoegen P; Eichkorn T; Held T; Ristau J; Rippke C; König L; Thomas M; Winter H; Adeberg S; Debus J; Klüter S; Hörner-Rieber J
    Front Oncol; 2021; 11():757031. PubMed ID: 35087746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereotactic ablative radiotherapy of 60 Gy in eight fractions is safe for ultracentral non-small cell lung cancer.
    Yang D; Cui J; Zhao J; You J; Yu R; Yu H; Jiang L; Li D; Xu B; Shi A
    Thorac Cancer; 2020 Mar; 11(3):754-761. PubMed ID: 32012484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Outcomes of Stereotactic MR-Guided Adaptive Radiation Therapy for High-Risk Lung Tumors.
    Finazzi T; Haasbeek CJA; Spoelstra FOB; Palacios MA; Admiraal MA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):270-278. PubMed ID: 32105742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis.
    Yoon SM; Luterstein E; Chu FI; Cao M; Lamb J; Agazaryan N; Low D; Raldow A; Steinberg ML; Lee P
    Cancer Med; 2021 Sep; 10(17):5897-5906. PubMed ID: 34288538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
    Nguyen KNB; Hause DJ; Novak J; Monjazeb AM; Daly ME
    Pract Radiat Oncol; 2019 Mar; 9(2):e196-e202. PubMed ID: 30496842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Stereotactic Body Radiotherapy in Ultracentral Lung Tumors Using a Risk-optimized Fractionation Scheme.
    Regnery S; Eichkorn T; Weykamp F; Held T; Weusthof K; Dinges LA; El-Shafie RA; Winter H; Thomas M; Debus J; Adeberg S; Hörner-Rieber J
    Clin Lung Cancer; 2021 Jul; 22(4):332-340.e3. PubMed ID: 33281061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.
    Michalet M; Bordeau K; Cantaloube M; Valdenaire S; Debuire P; Simeon S; Portales F; Draghici R; Ychou M; Assenat E; Dupuy M; Gourgou S; Colombo PE; Carrere S; Souche FR; Aillères N; Fenoglietto P; Azria D; Riou O
    Front Oncol; 2022; 12():842402. PubMed ID: 35356227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
    Karasawa K; Hayakawa S; Machitori Y; Shibata Y; Ogawa H; Ito K; Shimizuguchi T; Kawamoto T; Nihei K
    Technol Cancer Res Treat; 2018 Jan; 17():1533033818806318. PubMed ID: 30317929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of On-Table Plan Adaptation in MR-Guided Ablative Radiation Therapy for Central Lung Tumors.
    Finazzi T; Palacios MA; Spoelstra FOB; Haasbeek CJA; Bruynzeel AME; Slotman BJ; Lagerwaard FJ; Senan S
    Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):933-941. PubMed ID: 30928360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stereotactic ablative radiotherapy: a potentially curable approach to early stage multiple primary lung cancer.
    Chang JY; Liu YH; Zhu Z; Welsh JW; Gomez DR; Komaki R; Roth JA; Swisher SG
    Cancer; 2013 Sep; 119(18):3402-10. PubMed ID: 23798353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionated image-guided breath-hold SABR (stereotactic ablative body radiotherapy) of liver metastases--clinical results.
    Boda-Heggemann J; Dinter D; Weiss C; Frauenfeld A; Siebenlist K; Attenberger U; Ottstadt M; Schneider F; Hofheinz RD; Wenz F; Lohr F
    Radiat Oncol; 2012 Jun; 7():92. PubMed ID: 22710033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MR-guided adaptive versus ITV-based stereotactic body radiotherapy for hepatic metastases (MAESTRO): a randomized controlled phase II trial.
    Hoegen P; Zhang KS; Tonndorf-Martini E; Weykamp F; Regnery S; Naumann P; Lang K; Ristau J; Körber SA; Dreher C; Buchele C; Rippke C; Renkamp CK; Paul KM; König L; Büsch C; Krisam J; Sedlaczek O; Schlemmer HP; Niyazi M; Corradini S; Debus J; Klüter S; Hörner-Rieber J
    Radiat Oncol; 2022 Mar; 17(1):59. PubMed ID: 35346270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ultracentral Tumors Treated With Stereotactic Body Radiotherapy: Single-Institution Experience.
    Raman S; Yau V; Pineda S; Le LW; Lau A; Bezjak A; Cho BCJ; Sun A; Hope AJ; Giuliani M
    Clin Lung Cancer; 2018 Sep; 19(5):e803-e810. PubMed ID: 30007498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors.
    Chang JH; Poon I; Erler D; Zhang L; Cheung P
    Radiother Oncol; 2018 Nov; 129(2):277-283. PubMed ID: 30049454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial.
    Sun B; Brooks ED; Komaki R; Liao Z; Jeter M; McAleer M; Balter PA; Welsh JD; O'Reilly M; Gomez D; Hahn SM; Sepesi B; Rice DC; Heymach JV; Chang JY
    J Thorac Oncol; 2017 Jun; 12(6):983-992. PubMed ID: 28259750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a "no fly zone".
    Chang JY; Li QQ; Xu QY; Allen PK; Rebueno N; Gomez DR; Balter P; Komaki R; Mehran R; Swisher SG; Roth JA
    Int J Radiat Oncol Biol Phys; 2014 Apr; 88(5):1120-8. PubMed ID: 24661665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SMART ablation of lymphatic oligometastases in the pelvis and abdomen: Clinical and dosimetry outcomes.
    Regnery S; Buchele C; Piskorski L; Weykamp F; Held T; Eichkorn T; Rippke C; Katharina Renkamp C; Klüter S; Ristau J; König L; Koerber SA; Adeberg S; Debus J; Hörner-Rieber J
    Radiother Oncol; 2022 Mar; 168():106-112. PubMed ID: 35121031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term outcomes in patients with central and ultracentral non-small cell lung cancer treated with stereotactic body radiotherapy: single-institution experience.
    Song X; Zhao L; Jiang N; Ding N; Zong D; Zhang N; Wang D; Wen J; He X; Kong C; Zhu X
    Curr Probl Cancer; 2023 Jun; 47(3):100956. PubMed ID: 36966677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.